Cargando…
Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo
BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) is an animal model that captures many of the hallmarks of human multiple sclerosis (MS), including blood–brain barrier (BBB) breakdown, inflammation, demyelination and axonal destruction. The standard clinical score measurement of disease s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225609/ https://www.ncbi.nlm.nih.gov/pubmed/24237884 http://dx.doi.org/10.1186/1742-2094-10-138 |
_version_ | 1782343541037465600 |
---|---|
author | Eaton, Valerie L Vasquez, Kristine O Goings, Gwendolyn E Hunter, Zoe N Peterson, Jeffrey D Miller, Stephen D |
author_facet | Eaton, Valerie L Vasquez, Kristine O Goings, Gwendolyn E Hunter, Zoe N Peterson, Jeffrey D Miller, Stephen D |
author_sort | Eaton, Valerie L |
collection | PubMed |
description | BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) is an animal model that captures many of the hallmarks of human multiple sclerosis (MS), including blood–brain barrier (BBB) breakdown, inflammation, demyelination and axonal destruction. The standard clinical score measurement of disease severity and progression assesses functional changes in animal mobility; however, it does not offer information regarding the underlying pathophysiology of the disease in real time. The purpose of this study was to apply a novel optical imaging technique that offers the advantage of rapid imaging of relevant biomarkers in live animals. METHODS: Advances in non-invasive fluorescence molecular tomographic (FMT) imaging, in combination with a variety of biological imaging agents, offer a unique, sensitive and quantifiable approach to assessing disease biology in living animals. Using vascular (AngioSense 750EX) and protease-activatable cathepsin B (Cat B 680 FAST) near infrared (NIR) fluorescence imaging agents to detect BBB breakdown and inflammation, respectively, we quantified brain and spinal cord changes in mice with relapsing-remitting PLP(139-151)-induced EAE and in response to tolerogenic therapy. RESULTS: FMT imaging and analysis techniques were carefully characterized and non-invasive imaging results corroborated by both ex vivo tissue imaging and comparison to clinical score results and histopathological analysis of CNS tissue. FMT imaging showed clear differences between control and diseased mice, and immune tolerance induction by antigen-coupled PLGA nanoparticles effectively blocked both disease induction and accumulation of imaging agents in the brain and spinal cord. CONCLUSIONS: Cat B 680 FAST and AngioSense 750EX offered the combination best able to detect disease in both the brain and spinal cord, as well as the downregulation of disease by antigen-specific tolerance. Non-invasive optical tomographic imaging thus offers a unique approach to monitoring neuroinflammatory disease and therapeutic intervention in living mice with EAE. |
format | Online Article Text |
id | pubmed-4225609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42256092014-11-11 Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo Eaton, Valerie L Vasquez, Kristine O Goings, Gwendolyn E Hunter, Zoe N Peterson, Jeffrey D Miller, Stephen D J Neuroinflammation Research BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) is an animal model that captures many of the hallmarks of human multiple sclerosis (MS), including blood–brain barrier (BBB) breakdown, inflammation, demyelination and axonal destruction. The standard clinical score measurement of disease severity and progression assesses functional changes in animal mobility; however, it does not offer information regarding the underlying pathophysiology of the disease in real time. The purpose of this study was to apply a novel optical imaging technique that offers the advantage of rapid imaging of relevant biomarkers in live animals. METHODS: Advances in non-invasive fluorescence molecular tomographic (FMT) imaging, in combination with a variety of biological imaging agents, offer a unique, sensitive and quantifiable approach to assessing disease biology in living animals. Using vascular (AngioSense 750EX) and protease-activatable cathepsin B (Cat B 680 FAST) near infrared (NIR) fluorescence imaging agents to detect BBB breakdown and inflammation, respectively, we quantified brain and spinal cord changes in mice with relapsing-remitting PLP(139-151)-induced EAE and in response to tolerogenic therapy. RESULTS: FMT imaging and analysis techniques were carefully characterized and non-invasive imaging results corroborated by both ex vivo tissue imaging and comparison to clinical score results and histopathological analysis of CNS tissue. FMT imaging showed clear differences between control and diseased mice, and immune tolerance induction by antigen-coupled PLGA nanoparticles effectively blocked both disease induction and accumulation of imaging agents in the brain and spinal cord. CONCLUSIONS: Cat B 680 FAST and AngioSense 750EX offered the combination best able to detect disease in both the brain and spinal cord, as well as the downregulation of disease by antigen-specific tolerance. Non-invasive optical tomographic imaging thus offers a unique approach to monitoring neuroinflammatory disease and therapeutic intervention in living mice with EAE. BioMed Central 2013-11-15 /pmc/articles/PMC4225609/ /pubmed/24237884 http://dx.doi.org/10.1186/1742-2094-10-138 Text en Copyright © 2013 Eaton et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Eaton, Valerie L Vasquez, Kristine O Goings, Gwendolyn E Hunter, Zoe N Peterson, Jeffrey D Miller, Stephen D Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo |
title | Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo |
title_full | Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo |
title_fullStr | Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo |
title_full_unstemmed | Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo |
title_short | Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo |
title_sort | optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225609/ https://www.ncbi.nlm.nih.gov/pubmed/24237884 http://dx.doi.org/10.1186/1742-2094-10-138 |
work_keys_str_mv | AT eatonvaleriel opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo AT vasquezkristineo opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo AT goingsgwendolyne opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo AT hunterzoen opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo AT petersonjeffreyd opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo AT millerstephend opticaltomographicimagingofnearinfraredimagingagentsquantifiesdiseaseseverityandimmunomodulationofexperimentalautoimmuneencephalomyelitisinvivo |